Literature DB >> 18027666

[Protection effect of Wenxin Keli on isoproterenol induced heart failure in rats].

Fen Zhou1, Shen-jiang Hu, Yun Mu.   

Abstract

OBJECTIVE: To study the treatment effect of Wenxin Keli on isoproterenol (ISO) induced heart failure in rats.
METHOD: Sixty six-week old male Wistar rats were randomized into six groups. The rats in control group were only receive distilled water every day. The rats in ISO group also received two subcutaneous injections (85 mg x kg(-1)) of ISO, which were separated by a 24 hour interval and began to receive distilled water 2 weeks later every day. The rats in Wenxin Keli and control group were receive Wenxin Keli (9 mg x kg(-1)) every day. The rats in Wenxin Keli and ISO group received two subcutaneous injections (85 mg x kg(-1)) of ISO, which were separated by a 24 hour interval and began to receive Wenxin Keli (9 mg x kg(-1)) 2 weeks later every day. The rats in valsartan and control group were receive valsartan every day. The rats in valsartan and ISO group received two subcutaneous injections (85 mg x kg(-1)) of ISO, which were separated by a 24 hour interval and began to receive valsartan 30 mg x kg(-1) 2 weeks later every day. Echocardiogram measurement in rats were carried out after 4 weeks and 10 weeks feeding medince of hemodynamic measurement and aconitine induced arrhythmia in rats were carried out after 10 weeks. RESULT: Echocardiogram indicated that left ventricular internal diameter at diastolic phase (LVIDd), left ventricular internal diameter at systolic phase (LVIDs), LV percent fractional shortening (FS) and LV ejection fraction (EF) were decreased in the ISO group. Treatment with valsartan 4 weeks later, FS and EF were increased compared with the ISO group and 10 weeks later, LVIDd, LVIDs, FS, EF were increased. However, treatment with Wenxin Keli 10 weeks later, LVIDs, FS, EF were not changed obviously. Hemodynamic measurement showed that left ventricular end diastolic pressure (LVEDP), left ventricular systolic pressure (LVSP), and dp/dt(max) were improved after 10 weeks of treatment with valsartan. The LVEDP was decreased and dp/dt(max), was increased after 10 weeks of treatment with Wenxin Keli. Aconitine induced arrhythmia in rats in Wenxin Keli and control group were less serious than those in control group, aconitine induced arrhythmia in rats in Wenxin Keli and ISO group were less serious than those in ISO group.
CONCLUSION: Wenxin Keli could greatly improve the ISO induced cardiac dysfunction and protect the aconitine-induced arrhythmia in rats.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18027666

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  4 in total

1.  Oleuropein attenuates the progression of heart failure in rats by antioxidant and antiinflammatory effects.

Authors:  Zeinab Janahmadi; Ali Akbar Nekooeian; Ali Reza Moaref; Masoomeh Emamghoreishi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-12-08       Impact factor: 3.000

2.  Effect of Wenxin Keli and quinidine to suppress arrhythmogenesis in an experimental model of Brugada syndrome.

Authors:  Yoshino Minoura; Brian K Panama; Vladislav V Nesterenko; Matthew Betzenhauser; Hector Barajas-Martínez; Dan Hu; José M Di Diego; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2013-03-14       Impact factor: 6.343

3.  Effects of wenxin keli on the action potential and L-type calcium current in rats with transverse aortic constriction-induced heart failure.

Authors:  Yu Chen; Yang Li; Lili Guo; Wen Chen; Mingjing Zhao; Yonghong Gao; Aiming Wu; Lixia Lou; Jie Wang; Xiaoqiu Liu; Yanwei Xing
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-11       Impact factor: 2.629

4.  The effects of wenxin keli on left ventricular ejection fraction and brain natriuretic Peptide in patients with heart failure: a meta-analysis of randomized controlled trials.

Authors:  Yu Chen; Xingjiang Xiong; Chunmei Wang; Chenggang Wang; Ying Zhang; Xingyong Zhang; Yonghong Gao; Yanhui Xing; Jun Li; Jie Wang; Xiaoqiu Liu; Yanwei Xing
Journal:  Evid Based Complement Alternat Med       Date:  2014-04-27       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.